Status: Not yet recruiting
Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy
This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).
Participants needed: 16
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Saurabh DahiyaUpdated: Aug 27, 2026Locations: 1
Eligibility criteria
Diagnosis of primary chronic immune thrombocytopenia (ITP) or warm autoimmune he... [+25]
For ITP - ITP Bleeding Scale Grade 3 or higher at the screening visit (with the... [+26]